MFDS
No. 4490
MFDS manufacturing licence
No. 4490 — active since 2014
MFDS lookup →About GANA R&D
MFDS manufacturing licence
No. 4490
active since 2014
The manufacturer named on the registration.
GANA R&D Co., Ltd. formulates, fills and registers dermal fillers and wound dressings under its own name at one licensed site in Seongnam, Korea. This page is the identity check behind every registration number on this site.
- Legal name
- GANA R&D Co., Ltd. (주식회사 가나알엔디)
- Manufacturing site
- 555 Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do 13215, Republic of Korea (Seonil Technopia)
- Telephone
- +82-31-733-0242
01 Legal entity
One company, one licence, one site.
GANA R&D Co., Ltd. holds MFDS medical device manufacturing licence No. 4490, active since 2014. Every product on this site is registered with GANA R&D as the manufacturer of record.
The manufacturing site is in Seongnam, Gyeonggi-do — the same address on every registration.
02 What we make
Formulated, filled and registered under our own name.
Dermal fillers across four chemistries — hyaluronic acid, PLLA, PCL and calcium — plus PN / PDRN products, and hydrogel and foam wound dressings for hospitals and long-term care.
We also develop and manufacture under contract for partner brands, from formulation to scale-up, on the same licence and the same site.
- Dermal fillersMedical Aesthetics Four chemistries plus PN / PDRN, each registered under GANA R&D.→
- Wound dressingsWound Care Hydrogel and foam dressings, including domestic-sale approval in Korea.→
- Contract manufactureCo-development OEM / ODM development and licensed manufacture for partner brands.→
03 On the record
Four credentials a buyer can verify.
Each credential links to the public register that holds it. Product-level registrations are listed in full under Registrations & Market Access.
MFDS · KCL
KCL-ABBA-19926
MFDS GMP conformity
KCL-ABBA-19926 — valid 4 Mar 2024 to 3 Mar 2027
MFDS GMP status →EUDAMED
KR-MF-000037221
EUDAMED actor registration
KR-MF-000037221 — Manufacturer, active
EUDAMED search →MHRA
MAN_ID 32678
MHRA manufacturer registration
MAN_ID 32678 — updated 11 Apr 2026
MHRA PARD →KR · RU · BR · UK
34
Active product registrations
34 registrations across 4 jurisdictions
See the full list →04 Manufacturing site
Where the work is done.
Cleanroom formulation and filling, labelling and packaging, and freeze-drying are carried out on site in Seongnam under the GMP conformity certificate above. Capacity figures are given on request.
05 Founder
Dr. Yongho Park
Dr. Yongho Park founded GANA R&D in 2014 to manufacture dermal fillers under a Korean medical device licence, and later established GANA Cosmetic and Dr. Park CDMO on the same site.
He remains the principal decision-maker. Partners and buyers deal with him directly, and decisions are taken without a committee.
06 Timeline
Twelve years on one licence.
- 2014GANA R&D incorporated. MFDS manufacturing licence No. 4490. First registrations: GANALIFT and GANA FILL.
- 2015GANA PATCH foam and GANA HA registered in Korea.
- 2020GANA PATCH hydrogel wound dressing approved for domestic sale in Korea.
- 2021First registrations outside Korea: Russia and Brazil. MHRA manufacturer registration in the United Kingdom.
- 2022Ten Korean registrations in one year, including Filler-X PLUS, GANA PH and GANA PN.
- 2023EUDAMED manufacturer registration (SRN). Filler X registered in Korea.
- 2024GMP conformity renewed to March 2027. GANA PATCH, GANA BOOSTER and GANA PH registered in Russia.
- 2025GANA Filler X and GANA CH registered in Russia. New Korean registrations: MESOTEN H, REVACOLL and GANA AH8.
07 Dr. Park Group
One of five companies, each under its own name.
Dr. Park Group is the name under which five companies founded by Dr. Yongho Park present themselves together: GANA R&D, GANA Cosmetic, Dr. Park CDMO, Dr. Park Pharmaceutical and NeuroDP Therapeutics. Each company holds its own licences and registrations and is responsible for its own products.
Questions about the manufacturer?
Regulatory, quality and distribution enquiries are answered by GANA R&D directly.